CAR T Cells Targeting GD2 Feasible, Safe for Pediatric Neuroblastoma
GD2-targeted CAR T cells expanded in vivo, and were detectable in peripheral blood up to 30 months after infusion.
Diagnosis & Disease Information
Novel Treatment Gains Accelerated Approval for Relapsed/Refractory Neuroblastoma
Approval was based on results from two phase 2 single-arm, open-label trials that demonstrated overall response rate and duration of response.
Childhood Neuroblastoma Survivors at Risk for Psych Impairment
Psychological impairment seen particularly in survivors with chronic health conditions.
Double Autologous HCT Improves Outcomes in High-risk Pediatric Neuroblastoma
Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.
New Therapy Holds Potential for Neuroblastoma Treatment
A new therapy might help treat a rare, high-risk cancer that begins development in the fetus or embryo, neuroblastoma, according to recent results from cell culture experiments.
Novel Drug Effective in Treatment Resistant Pediatric Neuroblastoma
Researchers in pediatric oncology identified a powerful new drug with unparalleled strength against neuroblastomas that resist treatment with crizotinib.
Targeted Chemotherapy Shows Early Signs of Slowing Tumor Growth With Less Toxicity
Surviving neuroblastoma as a child can come with just as many challenges as the cancer itself. But a team of surgeons is in the nascent stages of developing a more targeted method for delivering chemotherapy, with lower toxicity.
Promising phase 1 results for difluoromethylornithine in neuroblastoma
In the first clinical trial of difluoromethylornithine (DFMO), an investigational agent for children suffering from neuroblastoma, side effects were minimal and patients saw long-term survival.
Identifying mutations in relapsed pediatric neuroblastoma may lead to better treatment options
Majority of pediatric patients with relapsed neuroblastoma studied harbored mutations that promoted RAS-MAPK pathway signaling.
FDA greenlights dinutuximab to treat high-risk neuroblastoma
First approval for a therapy aimed specifically to treat the rare pediatric cancer
- Loading...
Loading...
Loading... 
Loading...